{"prompt": "['MCW', 'OUTPATIENT', 'CPX-351', 'TRIAL', 'MCWCC', 'Medical College of Wisconsin Cancer Center', 'MDS', 'Myelodysplastic Syndromes', 'MTD', 'Maximum Tolerated Dose', 'NCI', 'National Cancer Institute', 'NIH', 'National Institutes of Health', 'OHRP', 'Office for Human Research Protections', 'ORR', 'Overall Response Rate', 'PD', 'Disease Progression', 'PI', 'Principal Investigator', 'PK', 'Pharmacokinetics', 'PR', 'Partial Response', 'PRO', 'Patient-reported Outcome', 'PRO-', 'Patient Reported Outcomes-Common Terminology Criteria for Adverse Events', 'CTCAE', 'QA', 'Quality Assurance', 'QOL', 'Quality of Life', 'RBC', 'Red Blood Cell (Count)', 'SAE', 'Serious Adverse Event', 'SD', 'Stable Disease', 'sIRB', 'Single Institutional Review Board', 'SOP', 'Standard Operating Procedure', 'SOTD', 'Successful Outpatient Treatment Delivery', 'SRC', 'Scientific Review Committee', 'SUSAR', 'Suspected Unexpected Serious Adverse Reaction', 't-AML', 'Therapy-related Acute Myeloid Leukemia', 'ULN', 'Upper Limit of Normal', 'UP', 'Unanticipated Problem', 'UPIRSO', 'Unanticipated Problems Involving Risks to Subjects or Others', 'WBC', 'White Blood Cell (count)', 'MCW Protocol No: IIT-Michaelis-OutpatientCPX-351', 'p14', 'Version No.: 3', 'Version Date: 04/15/2020']['MCW', 'OUTPATIENT', 'CPX-351', 'TRIAL', '1 BACKGROUND AND RATIONALE', 'Background', 'Otherwise fit adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)', 'may achieve cure with intensive induction or reinduction (salvage) chemotherapy. Traditionally, care is', 'provided in an inpatient environment, a model developed in the early days of treating children with acute', 'lymphocytic leukemia (ALL) with multi-agent induction therapy and used in adults due to the need for', 'frequent transfusions and the risks for treatment-related mortality from sepsis. [1,2] Accordingly, most', 'subjects who get induction therapy for AML receive this therapy as inpatients and are typically', 'discharged only after neutrophil recovery. The result is that the vast majority of subjects receiving', 'cytotoxic induction or reinduction therapy will be hospitalized for between three to five weeks. Subjects', 'who have relapsed and receive a salvage therapy for reinduction are often hospitalized are treated under a', 'similar practice pattern. [3]', 'In the last decade, there has been increasing interest in alternatives to care delivery models in hematologic', 'malignancies. [4,5,6] For example, there have been published studies about the safety of autologous and', 'allogeneic stem-cell transplants performed in a largely outpatient setting. [7,8] Improvements in', 'supportive care, especially effective, prophylactic oral antimicrobials, have led to a substantial reduction', 'in the risk for infection during induction. Similarly, the ability to administer red blood cell and platelet', 'transfusions in the outpatient setting has increased. [9,10] While not robust, there is some literature', 'supporting the psychological and economic benefits of outpatient treatment. [11] In fact, several cost', 'analyses have shown that the prolonged inpatient stays are a key driver of the exceedingly high costs of', 'leukemia care. [12-15] Routinely, chemotherapy regimens of similar intensity are used for AML', 'consolidation therapy and many subjects are discharged for follow-up as outpatients.', 'One large, single-institution pilot study has been published on the feasibility and safety of an early', 'discharge model of care for a select group of subjects after completion of intensive induction therapy for', 'AML or MDS. [16-18] The results of a pilot study were published in 2015. In this study, Dr. Roland', 'Walter and colleagues enrolled 178 AML subjects in a clinical trial of early discharge after induction', 'therapy. Investigators had predesignated medical and social/logistical criteria in order to participate in the', 'early discharge program. Of the 178 subjects, all met medical criteria for discharge, but only 107 met both', 'medical and logistical criteria. The remaining 29 served as inpatient controls. Researchers found that the', 'early discharge was feasible and appeared to result in a decrease in resource utilization without significant', 'impact on subject safety.', 'Liposomal Daunorubicin and Cytarabine (CPX-351)', 'In the last year, new data has led to the approval of a novel induction regimen for AML: a liposomal', 'formulation of daunorubicin and cytarabine. Unlike the traditional regimen of 7+3 (daunorubicin', 'administered by bolus IV on days 1,2 and 3 and cytarabine administered as a 24-hour continuous infusion', 'over days 1-7), CPX-351 is administered on days 1, 3 and 5 via intravenous infusion over 90 minutes and', 'on days 1 and 3 for subsequent cycles of induction, if needed. This agent is approved for subjects with', 'newly diagnosed AML with myelodysplastic-related changes or that is secondary to prior chemotherapy.', 'With the advent of this formulation, subjects being induced may not need to be hospitalized merely for', 'the 24-hour infusion of cytarabine, as had been the case in the past.', 'Among the most notable findings of the early studies of CPX-351 has been the relative mitigation of', 'traditional toxicities seen with 7+3, presumably because of the liposomal formulation. Conventional drug', 'administration can lead to changing drug ratios after dosing, thus, preventing the maintenance of any', 'MCW Protocol No: IIT-Michaelis-OutpatientCPX-351', 'p15', 'Version No.: 3', 'Version Date: 04/15/2020']\n\n###\n\n", "completion": "END"}